Relevant news and research

18C.3 Health risks of heated tobacco products

Last updated September 2018

Research:


Tobacco in Australia
Facts & Issues


tobaccoinaustralia.org.au
Tobacco in Australia
Facts & Issues


Halpern-Felsher, Bonnie, McKelvey, Karma, Popova, Lucy, Kim, Minji, Chaffee, Benjamin, Vijayaraghavan, Maya, Ling, Pamela, Lempert, Lauren K, Glantz, S. The evidence cited in PMI’s MRTP Application indicates that the proposed labeling and warnings for IQOS will mislead consumers, particularly youth, about the product. UCSF Center for Tobacco Control, Research and Education, Dec 2017. Available from: https://tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/iQOS%20MRTP%20comment%20Warnings_Dec%208-final.pdf


Tobacco in Australia
Facts & Issues


News reports:


Tobacco in Australia
Facts & Issues


Chun, Lauren F, Moazed, Farzad , Matthay, Michael A, Calfee, Carolyn S and Gotts, Jeffrey E. PMI’s MRTP application for IQOS does not adequately evaluate potential for hepatotoxicity risk. University of California San Francisco

https://tobaccoinaustralia.org.au
Tobacco in Australia
Facts & Issues


St.Helen, Gideon, Jacob, Peyton, Nardone, Natalie and Benowitz, Neal L. Because PMI application did not report the full range of HPHCs in IQOS aerosol, characterize HPHCs in sidestream emissions, include a non-targeted analysis of chemicals in emissions, or conduct clinical studies to describe exposure to toxicants during dual use with other tobacco products, FDA must deny PMI’s application. University of California San Francisco, 2017. Nov 29, 2017. Available from: https://tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/Gideon-ClinPharm_Comments%20on%20aerosol%20and%20exposure_IQOS_11292017-FINAL.pdf


